Stay updated on Efgartigimod in Post-COVID-19 POTS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.

Latest updates to the Efgartigimod in Post-COVID-19 POTS Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated to include new information about the efficacy and safety study of Efgartigimod in adults with post-COVID-19 POTS, including results and specific metrics for evaluating patient symptoms. Additionally, the timeline for the modernization of ClinicalTrials.gov data ingest has been set for June 2025.SummaryDifference51%
- Check9 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check38 days agoChange DetectedThe page has been updated to indicate that results have been submitted, replacing the previous message that no results were posted.SummaryDifference0.1%
- Check45 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a clinical study on efgartigimod for post-COVID-19 postural orthostatic tachycardia syndrome (POTS) and the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference35%
- Check52 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Efgartigimod in Post-COVID-19 POTS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.